Trials / Withdrawn
WithdrawnNCT00682721
Valacyclovir Suppression to Improve the Stability of Vaginal Flora Among HSV-2 Seropositive Women
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of Pittsburgh · Academic / Other
- Sex
- Female
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Not accepted
Summary
We will be examining the effects of suppressive valacyclovir therapy on the stability of vaginal flora in women who are seropositive for HSV-2. We have preliminary data that suggests the presence of HSV-2 increases the risk for Group B Streptococcus colonization as well as many other deleterious organisms (e.g. Streptococcus pseudoporcinus), in addition to increasing the risk for acquisition of BV-associated vaginal flora. We will be examining the effects of suppressive therapy on the vaginal flora of any HSV-2 seropositive woman.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Matching placebo two pills once daily |
| DRUG | Valacyclovir | 1 gram daily x number of days active in the study |
Timeline
- Start date
- 2009-02-01
- Primary completion
- 2010-09-01
- Completion
- 2010-09-01
- First posted
- 2008-05-22
- Last updated
- 2012-03-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00682721. Inclusion in this directory is not an endorsement.